NasdaqGS - Nasdaq Real Time Price USD
Trinity Biotech plc (TRIB)
As of 3:07 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
59,126.0000
56,832.0000
62,521.0000
81,149.0000
101,980.0000
Cost of Revenue
37,995.0000
37,382.0000
45,253.0000
47,695.0000
53,400.0000
Gross Profit
21,131.0000
19,450.0000
17,268.0000
33,454.0000
48,580.0000
Operating Expense
31,546.0000
35,393.0000
30,788.0000
27,000.0000
30,722.0000
Operating Income
-10,415.0000
-15,943.0000
-13,520.0000
6,454.0000
17,858.0000
Net Non Operating Interest Income Expense
-6,102.0000
-8,977.0000
-11,303.0000
-5,862.0000
-6,715.0000
Other Income Expense
-3,916.0000
-12,007.0000
-18,957.0000
-2,516.0000
-17,776.0000
Pretax Income
-20,433.0000
-36,927.0000
-43,780.0000
-1,924.0000
-6,633.0000
Tax Provision
-102.0000
-59.0000
-194.0000
-74.0000
-620.0000
Net Income Common Stockholders
-20,334.0000
-24,018.0000
-41,009.0000
875.0000
-6,388.0000
Diluted NI Available to Com Stockholders
-20,334.0000
-24,018.0000
-41,009.0000
875.0000
-6,388.0000
Basic EPS
-2.33
-3.20
-6.08
0.20
-1.60
Diluted EPS
-2.33
-3.20
-6.08
0.20
-1.60
Basic Average Shares
9,099.8110
7,654.9700
6,746.9660
4,180.3400
4,180.3400
Diluted Average Shares
10,345.6440
8,900.8030
6,746.9660
5,325.9320
5,251.2370
Total Operating Income as Reported
-13,426.0000
-27,045.0000
-19,349.0000
3,938.0000
82.0000
Total Expenses
69,541.0000
72,775.0000
76,041.0000
74,695.0000
84,122.0000
Net Income from Continuing & Discontinued Operation
-20,334.0000
-24,018.0000
-41,009.0000
875.0000
-6,388.0000
Normalized Income
-16,431.5634
-24,877.1889
-24,710.0164
573.0769
10,103.6635
Interest Income
298.0000
--
--
3.0000
36.0000
Interest Expense
7,571.0000
10,148.0000
11,532.0000
5,447.0000
5,535.0000
Net Interest Income
-6,102.0000
-8,977.0000
-11,303.0000
-5,862.0000
-6,715.0000
EBIT
-12,862.0000
-26,779.0000
-32,248.0000
3,523.0000
-1,098.0000
EBITDA
-10,959.0000
-25,002.0000
-29,915.0000
6,267.0000
1,979.0000
Reconciled Cost of Revenue
37,995.0000
37,382.0000
45,253.0000
47,695.0000
53,400.0000
Reconciled Depreciation
1,903.0000
1,777.0000
2,333.0000
2,744.0000
3,077.0000
Net Income from Continuing Operation Net Minority Interest
-20,331.0000
-36,868.0000
-43,586.0000
-1,850.0000
-6,013.0000
Total Unusual Items Excluding Goodwill
-3,919.0000
-12,010.0000
-18,960.0000
-2,520.0000
-17,779.0000
Total Unusual Items
-3,919.0000
-12,010.0000
-18,960.0000
-2,520.0000
-17,779.0000
Normalized EBITDA
-7,040.0000
-12,992.0000
-10,955.0000
8,787.0000
19,758.0000
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0001
Tax Effect of Unusual Items
-19.5634
-19.1889
-84.0164
-96.9231
-1,662.3365
12/31/2020 - 10/21/1992
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VVOS Vivos Therapeutics, Inc.
2.9200
+1.03%
BBLG Bone Biologics Corporation
1.2400
-1.59%
IINN Inspira Technologies Oxy B.H.N. Ltd.
1.3394
+1.49%
TIVC Tivic Health Systems, Inc.
0.2462
-1.08%
ALBIO.PA Biosynex SA
2.8800
+2.13%
MDAI Spectral AI, Inc.
1.0600
0.00%
RSLS ReShape Lifesciences Inc.
5.59
+10.91%
VERO Venus Concept Inc.
0.3067
+1.22%
OM Outset Medical, Inc.
0.7343
+1.19%
NUWE Nuwellis, Inc.
1.2296
-5.42%